A novel Artificial Intelligence Protocol to Investigate Potential Leads for Parkinson's Di

A novel AI protocol identified three potential drug candidates for Parkinson's disease from a Traditional Chinese Medicine database. The work by Zhidong Chen used molecular docking to screen compounds against four key proteins and built 3D-QSAR models based on known inhibitor activities. Candidate compounds 2007_22057, 2007_22325, and 2007_15317 were selected after molecular dynamics simulation.

Use Cases

• Validate molecular docking predictions for NLRP3 inhibitors based on the described AI protocol.
• Screen the TCM Database @Taiwan for other compounds with high affinity to HSP90AB1, CASP1, or TP53.
• Build or compare 3D-QSAR models for protein targets involved in Parkinson's disease pathogenesis.
• Investigate the drug-target interaction network formed by the top-scoring TCM compounds.
• Prioritize compounds for in vitro or in vivo testing based on the identified candidate IDs (2007_22057, 2007_22325, 2007_15317).

Strengths

• The description details a multi-step AI and simulation methodology for drug candidate identification.
• Specific candidate compound IDs (2007_22057, 2007_22325, 2007_15317) are named as potential leads.
• The protocol targets four specific proteins (NLRP3, HSP90AB1, CASP1, TP53) implicated in Parkinson's disease.

Limitations

• Row count and dataset size are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The data appears to be a research output from paperswithcode; its completeness as a standalone dataset is unclear.

Provenance

Source

paperswithcode

Collection Method

Molecular docking screening of the TCM Database @Taiwan, followed by 3D-QSAR modeling and molecular dynamics simulation.